Parkinson's disease (PD) is a common degenerative neurological disease, affecting approximately 1 million Americans. Advances in the treatment and management of PD over the past ten years have increasingly required general neurologists to seek advice from Movement Disorders specialists in order to optimize PD patient care. Specifically, Movement Disorders specialists are now managing patients considering and undergoing surgical treatments for PD (e.g. deep brain stimulation [DBS]), as well as routine clinical management for both early and late stage PD. Furthermore, with advances in the understanding of the pathophysiology of PD, new strategies for slowing the course of PD are emerging. As these therapies have begun to move to clinical trials, patient access to these trials has been and will likely continue to be primarily through PD centers. We have a network of PD specialists in or near Long Island, NY with a combination of practical experience in the management of PD, extensive clinical trial experience, and clinical research excellence related to the development of imaging methods for assessing therapies for PD. The Long Island region comprises a general population of approximately 5 million people, but our catchment area also includes parts of Manhattan, Queens, Brooklyn, and Staten Island. Our Movement Disorders Center currently follows approximately 2,500 PD patients, and we have participated or led >20 PD clinical trials;in total, we have enrolled 50 subjects in the NET-PD trials. With our combination of PD clinical trial and research experience and a very broad population base, we are uniquely positioned to continue participating successfully in the large-scale simple neuroprotective clinical trial for PD. This is supported by our highly successful recruitment of subjects to date.
The accumulated disability that PD causes is a major source of diminished quality of life and increased health care costs. Despite the advances in our understanding of the pathophysiology in PD, there are no current therapies that slow the inexorable clinical decline. LS1 will help to determine if creatine can slow clinical decline and provide better information on the course of early PD than is currently available.
|Wills, Anne-Marie A; Pérez, Adriana; Wang, Jue et al. (2016) Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1 JAMA Neurol 73:321-8|
|Wills, Anne-Marie A; Elm, Jordan J; Ye, Rong et al. (2016) Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord 33:127-133|
|Elm, Jordan J; NINDS NET-PD Investigators (2012) Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 27:1513-21|